| __timestamp | CRISPR Therapeutics AG | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 79696000 |
| Thursday, January 1, 2015 | 12573000 | 93236000 |
| Friday, January 1, 2016 | 42238000 | 150842000 |
| Sunday, January 1, 2017 | 69800000 | 150643000 |
| Monday, January 1, 2018 | 113773000 | 150252000 |
| Tuesday, January 1, 2019 | 179362000 | 140804000 |
| Wednesday, January 1, 2020 | 266946000 | 34236000 |
| Friday, January 1, 2021 | 438633000 | 35672000 |
| Saturday, January 1, 2022 | 461645000 | 66607000 |
| Sunday, January 1, 2023 | 387332000 | 76363000 |
| Monday, January 1, 2024 | 320653000 | 79048000 |
In pursuit of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, CRISPR Therapeutics AG and Halozyme Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, CRISPR Therapeutics AG increased its R&D spending by an impressive 25,500%, peaking in 2022. This surge underscores their aggressive pursuit of cutting-edge gene-editing technologies. In contrast, Halozyme Therapeutics, Inc. exhibited a more conservative approach, with a 4% decrease in R&D spending over the same period. Notably, their highest expenditure occurred in 2016, reflecting a strategic pivot. These trends highlight the diverse paths companies take in the biotech sector, balancing innovation with financial prudence. As the industry evolves, these spending patterns will likely shape the future of medical breakthroughs.
Research and Development Investment: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Research and Development Expenses Breakdown: United Therapeutics Corporation vs Halozyme Therapeutics, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
Research and Development Investment: Jazz Pharmaceuticals plc vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Viridian Therapeutics, Inc.
Research and Development Investment: Ultragenyx Pharmaceutical Inc. vs CRISPR Therapeutics AG
Viking Therapeutics, Inc. or CRISPR Therapeutics AG: Who Invests More in Innovation?
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Geron Corporation
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc.